Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)

X
Trial Profile

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tovinontrine (Primary) ; Hydroxycarbamide
  • Indications Sickle cell anaemia
  • Focus Adverse reactions; Proof of concept
  • Sponsors Imara Inc
  • Most Recent Events

    • 22 Nov 2021 According to an Imara Inc media release, the company expects to present updated 12-month VOC data from this trial at the American Society of Hematology Annual Meeting in December 2021.
    • 11 Jun 2021 Results (n-=93) published in the Imara Inc Media Release.
    • 11 Jun 2021 According to an Imara Inc media release, data from this trial were presented at the European Hematology Association (EHA) Annual Congress 2021, being held virtually.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top